Pipeline Overview

Armata’s therapeutic phage candidates aim to address areas of significant unmet clinical need, by targeting key antibiotic-resistant bacteria including those on the World Health Organization’s global priority pathogens list. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent are being developed in partnership with Merck. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing.

divider
Program Discovery Preclinical IND-Enabling Phase 1b/2 Partner
Pseudomonas aeruginosa
Respiratory Infections
AP-PA02
CF
AP-PA02
NCFB
 
AP-PA03
Pneumonia
Staphylococcus aureus
AP-SA02
Bacteremia
US DoD*
Bacteremia
PJI
 
Phage Candidate Program Phase Partner
AP-PA02
CF Phase 1b/2
NCFB IND-Enabling
AP-PA03
Pneumonia IND-Enabling  
AP-SA02
Bacteremia IND-Enabling US DoD*
PJI IND-Enabling

CF: cystic fibrosis; NCFB: non-CF bronchiectasis; PJI: prosthetic joint infection
SWARM-P.a. NCT Number; NCT04596319; Cystic Fibrosis Foundation TrialFinder
*Department of Defense (Naval Medical Research Center, US Army Medical Research Acquisition Activity, Defense Health Agency)

Discovery-Stage
Engineered Phage
undisclosed target/indication
Merck
Escherichia coli
Klebsiella pneumoniae
Discovery-Stage
Engineered Phage
undisclosed target/indication
Merck
Escherichia coli
Klebsiella pneumoniae